Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Fiche publication
Date publication
janvier 2017
Journal
Lancet (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G,
Lien Pubmed
Résumé
There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment. We aimed to assess the efficacy and safety of regorafenib in patients with HCC who have progressed during sorafenib treatment.
Mots clés
Aged, Antineoplastic Agents, adverse effects, Carcinoma, Hepatocellular, drug therapy, Double-Blind Method, Female, Humans, Kaplan-Meier Estimate, Liver Neoplasms, drug therapy, Male, Middle Aged, Niacinamide, analogs & derivatives, Phenylurea Compounds, adverse effects, Pyridines, adverse effects, Treatment Outcome
Référence
Lancet. 2017 01;389(10064):56-66